The investigational shot from Pfizer and Valneva demonstrated higher antibody levels in the three-dose vaccination schedule versus the two-dose vaccination schedule.
Earlier today, Pfizer and Valneva announced its investigational Lyme disease vaccine, VLA15, demonstrated that its antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule.
“Lyme disease continues to spread, representing a high unmet medical need that impacts the lives of many in the Northern Hemisphere, and each new report of positive data takes us a step closer to potentially bringing this vaccine to both adults and children who could benefit from it,” Valneva CMO Juan Carlos Jaramillo MD, said in a statement.
Read more at: https://www.contagionlive.com/view/lyme-disease-vaccine-shows-antibodies-6-months-after-completion
